At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Neem Mouthrinse +1 moredrug
Likely dose
Neem Mouthrinse 10mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Controlled Double-blinded Clinical Trial of an Herbal Mouthrinse for Radiotherapy Induced Mucositis in Cancer Patients
In Brief
A Phase 2 clinical trial evaluating Neem Mouthrinse and Placebo Mouthrinse for Oral Mucositis. Completed, enrolled 50 participants across 1 site.
Detailed Summary
This study involves adults receiving radiation therapy for head and neck cancer and will test whether or not the study mouthrinse may lessen oral mucositis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOral Mucositis
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedJul 2013
Primary CompletionApr 2015
Study CompletionJun 2015
TodayJul 2026
First PostedJul 12, 2013
Enrollment StartJul 1, 2013
Primary CompletionApr 1, 2015
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.0 years ago
Interventions
Neem Mouthrinsedrug
10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
Placebo Mouthrinsedrug
10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.